AHAbrochure.pdf = Circadian rhythms affect insulin resistance, obesity, inflammation, heart disease, dopamine
AHAbrochure.pdf (application/pdf Object)
Regulating the Regulator: Resetting Circadian Neurophysiology to reduce cardiometabolic risk and cardiovascular disease
Program Description:Cardiometabolic risk (insulin resistance syndrome) encompasses a range of simultaneous pathologies, including hypertension, dyslipidemia, insulin resistance, obesity, inflammation,and endothelial dysfunction, all with hypothalamic etiological components.
While genetic background and diet interact to potentiate the insulin resistance syndrome, it is the neuroendocrine axis that regulates gene expression and the impact of diet to control overall metabolism. Research indicates important roles for temporal shifts in circadian rhythms of hypothalamic neurochemistry in the development of the insulin resistance syndrome.
Marked annual cycles between the obese, insulin resistant and lean, insulin sensitive states are well preserved across evolutionary time among vertebrate species in the wild and these seasonal shifts occur without any change in genome and cannot be explained fully by changes in caloric intake. A key element in this endogenous metabolic shift control-system is hypothalamic circadian dopamine neurophysiology. Endogenous increases in hypothalamic dopamine activity at particular times of day function to initiate a hypothalamic neurophysiology operative in the reversal of the insulin resistance syndrome.
By mimicking the neuroendocrine dopaminergic activation driving the seasonal shift to the lean, insulin sensitive state it is possible to produce such shifts in metabolism among a wide variety of genetic and dietary induced animal models of insulin resistance as well.
Such findings have spawned clinical investigations of bromocriptine, a dopamine D2 receptor agonist, for the treatment of metabolic
disease, particularly cardiometabolic risk.
This symposium will review published data on a) preclinical studies of hypothalamic dopaminergic activities operative in the reversal of the insulin resistance syndrome and related metabolic disease and b) clinical studies demonstrating
the potential utility of hypothalamic dopamine neuromodulation in the treatment or prevention of insulin resistance syndrome, cardiovascular disease and type 2 diabetes.
Veroscience is apparently connecting the dots between circadian rhythm, dopamine, and insulin resistance.
See the book "sleep sugar and survival" by ts wiley for details.
Regulating the Regulator: Resetting Circadian Neurophysiology to reduce cardiometabolic risk and cardiovascular disease
Program Description:Cardiometabolic risk (insulin resistance syndrome) encompasses a range of simultaneous pathologies, including hypertension, dyslipidemia, insulin resistance, obesity, inflammation,and endothelial dysfunction, all with hypothalamic etiological components.
While genetic background and diet interact to potentiate the insulin resistance syndrome, it is the neuroendocrine axis that regulates gene expression and the impact of diet to control overall metabolism. Research indicates important roles for temporal shifts in circadian rhythms of hypothalamic neurochemistry in the development of the insulin resistance syndrome.
Marked annual cycles between the obese, insulin resistant and lean, insulin sensitive states are well preserved across evolutionary time among vertebrate species in the wild and these seasonal shifts occur without any change in genome and cannot be explained fully by changes in caloric intake. A key element in this endogenous metabolic shift control-system is hypothalamic circadian dopamine neurophysiology. Endogenous increases in hypothalamic dopamine activity at particular times of day function to initiate a hypothalamic neurophysiology operative in the reversal of the insulin resistance syndrome.
By mimicking the neuroendocrine dopaminergic activation driving the seasonal shift to the lean, insulin sensitive state it is possible to produce such shifts in metabolism among a wide variety of genetic and dietary induced animal models of insulin resistance as well.
Such findings have spawned clinical investigations of bromocriptine, a dopamine D2 receptor agonist, for the treatment of metabolic
disease, particularly cardiometabolic risk.
This symposium will review published data on a) preclinical studies of hypothalamic dopaminergic activities operative in the reversal of the insulin resistance syndrome and related metabolic disease and b) clinical studies demonstrating
the potential utility of hypothalamic dopamine neuromodulation in the treatment or prevention of insulin resistance syndrome, cardiovascular disease and type 2 diabetes.
Veroscience is apparently connecting the dots between circadian rhythm, dopamine, and insulin resistance.
See the book "sleep sugar and survival" by ts wiley for details.
Comments